Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has scheduled its first quarter 2025 financial results release for Thursday, May 1, 2025, before U.S. market opening.
The company will host a conference call and webcast at 8:00 a.m. ET where management will present the quarterly results and provide corporate development updates. Participants can access the call through a registration link that will provide dial-in details and a unique PIN. The webcast will be available through the company's Investor Relations website.
Fulcrum Therapeutics (FULC), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di piccole molecole per malattie genetiche rare, ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 per giovedì 1 maggio 2025, prima dell'apertura dei mercati statunitensi.
L'azienda terrà una conference call e webcast alle 8:00 a.m. ET, durante la quale il management presenterà i risultati trimestrali e fornirà aggiornamenti sullo sviluppo aziendale. I partecipanti potranno accedere alla chiamata tramite un link di registrazione che fornirà i dettagli per la chiamata e un PIN univoco. Il webcast sarà disponibile sul sito web delle Relazioni con gli Investitori dell'azienda.
Fulcrum Therapeutics (FULC), una compañía biofarmacéutica en etapa clínica especializada en el desarrollo de pequeñas moléculas para enfermedades genéticas raras, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el jueves 1 de mayo de 2025, antes de la apertura del mercado estadounidense.
La empresa realizará una llamada conferencia y webcast a las 8:00 a.m. ET, donde la dirección presentará los resultados trimestrales y proporcionará actualizaciones sobre el desarrollo corporativo. Los participantes podrán acceder a la llamada mediante un enlace de registro que ofrecerá los detalles para marcar y un PIN único. El webcast estará disponible a través del sitio web de Relaciones con Inversionistas de la compañía.
Fulcrum Therapeutics (FULC)는 희귀 유전 질환을 위한 소분자 개발에 특화된 임상 단계의 바이오제약 회사로, 2025년 1분기 재무 결과를 2025년 5월 1일 목요일 미국 시장 개장 전에 발표할 예정입니다.
회사는 동부 표준시 기준 오전 8시에 컨퍼런스 콜 및 웹캐스트를 진행하며, 경영진이 분기 실적을 발표하고 기업 개발 현황을 업데이트할 예정입니다. 참가자들은 등록 링크를 통해 전화 접속 정보와 고유 PIN을 받아 콜에 참여할 수 있습니다. 웹캐스트는 회사 투자자 관계 웹사이트에서 시청할 수 있습니다.
Fulcrum Therapeutics (FULC), une société biopharmaceutique en phase clinique spécialisée dans le développement de petites molécules pour les maladies génétiques rares, a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le jeudi 1er mai 2025, avant l'ouverture des marchés américains.
La société organisera une conférence téléphonique et un webcast à 8h00 ET lors desquels la direction présentera les résultats trimestriels et fournira des mises à jour sur le développement de l'entreprise. Les participants pourront accéder à l'appel via un lien d'inscription qui fournira les détails d'appel et un code PIN unique. Le webcast sera disponible sur le site des relations investisseurs de la société.
Fulcrum Therapeutics (FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von kleinen Molekülen für seltene genetische Erkrankungen spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für Donnerstag, den 1. Mai 2025, vor der Öffnung des US-Marktes, geplant.
Das Unternehmen wird eine Telefonkonferenz und Webcast um 8:00 Uhr ET abhalten, bei der das Management die Quartalsergebnisse vorstellen und Updates zur Unternehmensentwicklung geben wird. Teilnehmer können über einen Registrierungslink, der Einwahldaten und eine individuelle PIN bereitstellt, an dem Anruf teilnehmen. Der Webcast wird über die Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When will Fulcrum Therapeutics (FULC) release Q1 2025 earnings?
How can investors join FULC's Q1 2025 earnings call?
What time is Fulcrum Therapeutics' Q1 2025 earnings call?
Will there be a replay available for FULC's Q1 2025 earnings call?
